Aktiesnakken — Juli 2010
-
den nye aftale er så anderledes at de vil går igennem hele regnskabet
-
der er ingen ændring i 2010 milestones!
-
igen milestones på bendamustine paid in full
-
der kommer en reduction i udgifter for 2010
-
og cash vil overgå det der ligger i forventningerne idag
-
nu Jan
-
laser sharp focus på vores 100 day strategy
-
Der er nu total klarhed om arzerra omkostninger
-
vi har fået værdi fra onkologi
-
nu q&a
-
pengene fra GSK er ikke øremærket
-
fedt
-
lad os bruge dem på damer
-
David nu
-
max cash der går ud er 102 mill pund
-
men op til 145 mill pund
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind